Don't Fight The Momentum: Roivant Has Big Expectations, But Real Pipeline Momentum
Roivant’s $4 billion cash balance supports multiple late-stage immunology and pulmonary programs, including IMVT-1402, LISRAYA and…
Stephen Ayers NASDAQ
Immunovant, Inc.
IMVT
1 story
$6.3B Market cap · 2026-11-09
Get IMVT news in Claude, ChatGPT or your own code. See plans
Stephen Ayers Tickers on this page
Companies the stories above are also about, besides IMVT.
